Specify a stock or a cryptocurrency in the search bar to get a summary
Crinetics Pharmaceuticals Inc
CRNXCrinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California. Address: Building No. 2, San Diego, CA, United States, 92121
Analytics
WallStreet Target Price
46.82 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CRNX
Dividend Analytics CRNX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CRNX
Stock Valuation CRNX
Financials CRNX
Results | 2019 | Dynamics |